CClinicalTrials.gg
CompletedNCT01406925Updated Aug 1, 2011

Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers

A Phase 1 interventional study of Placebo control and NRL001 cream in Fecal Incontinence, sponsored by Norgine. Completed at 1 site in Bulgaria. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-08-01.

Sponsored by Norgine · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Study summary

This study is conducted to explore the safety and tolerability and plasma pharmacokinetics of NRL001 after single intra-anal dose of 1mL cream at increasing concentrations.

02

Conditions studied

  • Fecal Incontinence

Browse trials for

03

In context

Fecal Incontinence

312 studies on the registry are indexed under Fecal Incontinence; 57 are open to participants now.

This study's enrollment of 12 is below the median of 50 across 216 interventional studies indexed under Fecal Incontinence.

Browse Fecal Incontinence studies →

Lead sponsor

Norgine is the lead sponsor of 52 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

IN.1) sex: male and female (non-child-bearing potential or using medically adequate contraception

IN.2) race: Caucasian

IN.3) BW: 50 - 100 kg

IN.4) BMI: 20 - 28 kg.m-2

IN.5) age: 21 - 50 years

IN.6) type: healthy on the basis of specified criteria evaluated at the screening visit

IN.7) willing and able to provide informed consent

Exclusion criteria

Exclusion Criteria:

General

EX.1) Previous participation in the trial

EX.2) Participant in any other trial during the last 90 days

EX.3) Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months

EX.4) History of any clinically relevant allergy (including hypersensitivity to the trial medications)

EX.5) Presence of acute or chronic infection

EX.6) Presence or history of any relevant co-morbidity

EX.7) Resting systolic blood pressure > 140 or \< 90 mmHg, diastolic blood pressure > 95 or \< 50 mmHg

EX.8) Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular

EX.9) Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes

EX.10) Positive serology for HBsAg, anti HBc and anti HCV

EX.11) Positive HIV test

EX.12) Positive alcohol or urine drug test on recruitment (and upon admission)

EX.13) History of alcohol and/or drug abuse and/or daily use of > 30 gr alcohol

EX.14) Smoking more than 15 cigarettes/day or equivalent of other tobacco products

EX.15) Use of prohibited medication

EX.16) Suspicion or evidence that the subject is not trustworthy and reliable

EX.17) Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard

General - all females

EX.18) Positive pregnancy test

EX.19) Lactating

EX.20) Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods [condom, diaphragm with spermicidal gel] should be used in addition).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Placebo comparator
    Control

    Placebo control

    Drug: Placebo control

  • Experimental
    Low dose NRL001

    0.5% NRL001 cream

    Drug: NRL001 cream

  • Experimental
    Intermediate dose NRL001

    0.75% NRL001 cream

    Drug: NRL001 cream

  • Experimental
    High dose NRL001

    1.0% NRL001 cream

    Drug: NRL001 cream

Interventions

  • DrugPlacebo control

    Placebo cream

  • DrugNRL001 cream

    Cream for single-dose intra-anal application

06

What researchers measure

Primary outcomes

  1. Cmax of NRL001

    Time frame: 30 mins, 1, 2, 3, 4, 5, 6, 8 and 12 hours after dosing

Secondary outcomes

  1. AUC of NRL001

    Time frame: 30 mins, 1, 2, 3, 4, 5, 6, 8 and 12 hours after dosing

  2. Tolerability of NRL001

    Spontaneously reported adverse events will be recorded

    Time frame: Up to 12 hours post-dosing

07

Study locations

1 site
  • University Hospital MHAPT Zaritza Johanna
    Sofia, Bulgaria
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01406925
Lead sponsor
Norgine
First posted
Aug 1, 2011
Start date
Apr 2007
Primary completion
May 2007
Completion
Jun 2007
Last update
Aug 1, 2011

Study contacts

Hans Gruss, MD PhD
study director · Norgine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion